

**Altuviiiio™ [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl]**

Effective: December 1, 2023

<b>Guideline Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Non-Formulary <input type="checkbox"/> Step-Therapy <input type="checkbox"/> Administrative
-----------------------	---

**Applies to:**

**Commercial Products**

☒ Harvard Pilgrim Health Care Commercial products; Fax 617-673-0988

☒ Tufts Health Plan Commercial products; Fax 617-673-0988

CareLink<sup>SM</sup> – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization

**Public Plans Products**

☒ Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product); Fax 617-673-0988

**Note:** While you may not be the provider responsible for obtaining prior authorization, as a condition of payment you will need to ensure that prior authorization has been obtained.

## Overview

### Food and Drug Administration – Approved Indications

**Altuviiiio [antihemophilic factor (recombinant), Fc-VWF-TEN fusion protein-ehtl]** is a recombinant DNA-derived, Factor VIII concentrate indicated for use in for adults and children with Hemophilia A (congenital Factor VIII deficiency) for:

- Routine prophylaxis to reduce the frequency of bleeding episodes
- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding

Altuviiiio is not indicated for the treatment of von Willebrand disease.

### Clinical Guideline Coverage Criteria

The plan may authorize coverage of Altuviiiio for Members when all the following clinical criteria is met:

#### Initial Authorization Criteria

1. Documented diagnosis of hemophilia A

**AND**

2. Documentation the requested medication is being prescribed for **one (1)** of the following:
  - a. Routine prophylaxis to reduce the frequency of bleeding episodes
  - b. On-demand treatment and control of bleeding episodes
  - c. Perioperative management of bleeding

**AND**

3. Prescribed by or in consultation with a hematologist

## Reauthorization Criteria

1. Prescribed by or in consultation with a hematologist

**AND**

2. Documentation the Member has experienced a therapeutic response from Altuviio as defined by at least **one (1)** of the following:

- a. Reduced frequency of bleeds
- b. Reduced severity of bleeds

## Limitations

- Coverage of Altuviio for routine prophylaxis to reduce the frequency of bleeding episodes and on-demand treatment and control of bleeding episodes will be authorized for 12 months.
- Coverage of Alutviio for perioperative management of bleeding will be authorized for three (3) months.
- Members new to the plan stable on Alutviio should be reviewed against Reauthorization Criteria.

## Codes

The following code(s) require prior authorization:

**Table 1: HCPCS Codes**

HCPCS Codes	Description
J7214	Injection, Factor VIII/von Willebrand factor complex, recombinant (Altuviio), per Factor VIII IU

## References

1. Altuviio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] [package insert]. Waltham, MA; Bioverativ Therapeutics, Inc.: March 2023.

## Approval And Revision History

May 9, 2023: Reviewed by Pharmacy and Therapeutics Committee (P&T)

- April 19, 2023: Reviewed by the Medical Policy Approval Committee (MPAC)
- October 1, 2023: Administrative update: Added new J Code J7214 to Medical Necessity Guideline
- September 12, 2023: Updated diagnosis requirements and use requirements. Removed the requirement that the Member does not have von Willebrand disease. Added Reauthorization Criteria. Clarified the duration of approvals rules. Removed the following Limitation: "The Plan will cover Alutviio when Plan Criteria, is met or if the Member has severe disease with frequent bleeding episodes and/or frequency hospitalization" (effective 12/1/23).

## Background, Product and Disclaimer Information

Medical Necessity Guidelines are developed to determine coverage for benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. We make coverage decisions using these guidelines, along with the Member's benefit document, and in coordination with the Member's physician(s) on a case-by-case basis considering the individual Member's health care needs.

Medical Necessity Guidelines are developed for selected therapeutic or diagnostic services found to be safe and proven effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in our service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. We revise and update Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern. For Tufts Health Together (Medicaid), coverage may be available beyond these guidelines for pediatric members under age 21 under the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefits of the plan in accordance with 130 CMR 450.140 and 130 CMR 447.000, and with prior authorization.

Treating providers are solely responsible for the medical advice and treatment of Members. The use of this guideline is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to eligibility and benefits on the date of service, coordination of benefits, referral/authorization, utilization management guidelines when applicable, and adherence to plan policies, plan procedures, and claims editing logic.